Skip to main content
SpringerLink
Log in

IDegLira for type 2 diabetes: a systematic review and meta-analysis

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Objectives

IDegLira is a novel fixed-ratio soluble combination of insulin degludec and the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide approved for type 2 diabetes (T2D) patients. Individual trials have assessed the clinical profile of IDegLira vs different comparators. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of IDegLira for T2D.

Methods

PubMed, Embase, Cochrane Library and ClinicalTrials.gov were searched from inception to August 15, 2023. The primary outcomes included change from baseline in haemoglobin A1c (HbA1c) and body weight. Risk ratios (RR), mean differences (MD), and 95% confidence intervals (CI) were calculated to evaluate the outcomes.

Results

This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients. Compared with the control groups, IDegLira was optimal in change in HbA1c, percentage of patients achieving HbA1c < 7%, percentage of patients achieving HbA1c < 6.5%, HbA1c < 7.0% without weight gain and without severe or blood glucose (BG)-confirmed hypoglycaemia episodes, HbA1c < 6.5% without weight gain and without severe or BG-confirmed hypoglycaemia episodes, change in fasting plasma glucose, change in self-measured plasma glucose, change in systolic pressure, and total daily insulin dose. No difference was found between the IDegLira and control groups in terms of change in body weight, change in diastolic pressure, severe or BG-confirmed symptomatic hypoglycaemia, nocturnal severe or BG-confirmed symptomatic hypoglycaemia, adverse events or serious adverse events.

Conclusions

In patients with T2D, IDegLira improved glycaemic control whilst balancing out risk for hypoglycaemia and gastrointestinal side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. H. Sun, P. Saeedi, S. Karuranga et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119 (2022)

    Article  PubMed  Google Scholar 

  2. M.K. Ali, K.M. Bullard, J.B. Saaddine, C.C. Cowie, G. Imperatore, E.W. Gregg, Achievement of goals in U.S. diabetes care, 1999–2010. N. Engl. J. Med. 368(17), 1613–1624 (2013)

    Article  CAS  PubMed  Google Scholar 

  3. K.J. Lipska, X. Yao, J. Herrin et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 40(4), 468–475 (2017)

    Article  PubMed  Google Scholar 

  4. American Diabetes Association Professional Practice Committee, 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care 45(Suppl 1), S125–S143 (2022)

    Article  Google Scholar 

  5. W. Wang, B.F.R. Agner, B. Luo et al. DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs. J. Diabetes 14(6), 401–413 (2022)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. K. Kaku, E. Araki, Y. Tanizawa et al. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial. Diabetes Obes. Metab. 21(12), 2674–2683 (2019)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. S.C. Gough, B. Bode, V. Woo et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol 2(11), 885–893 (2014)

    Article  CAS  PubMed  Google Scholar 

  8. Y. Pei, B.R. Agner, B. Luo et al. DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin. Diabetes Obes. Metab. 23(12), 2687–2696 (2021)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. H. Watada, S. Kaneko, M. Komatsu et al. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial. Diabetes Obes. Metab. 21(12), 2694–2703 (2019)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. J.B. Buse, T. Vilsbøll, J. Thurman et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care 37(11), 2926–2933 (2014)

    Article  CAS  PubMed  Google Scholar 

  11. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58(3), 429–442 (2015)

    Article  PubMed  Google Scholar 

  12. P.D. Home, V.R. Aroda, L. Blonde et al. Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison. Diabetes Obes. Metab. 22(11), 2170–2178 (2020)

    Article  CAS  PubMed  Google Scholar 

  13. P. Liakopoulou, A. Liakos, D. Vasilakou et al. Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis. Endocrine 56(3), 485–494 (2017)

    Article  CAS  PubMed  Google Scholar 

  14. D. Moher, A. Liberati, J. Tetzlaff et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535 (2009)

    Article  PubMed  PubMed Central  Google Scholar 

  15. A. Liberati, D.G. Altman, J. Tetzlaff et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, b2700 (2009)

    Article  PubMed  PubMed Central  Google Scholar 

  16. S.P. Hozo, B. Djulbegovic, I. Hozo, Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol 5, 13 (2005)

    Article  PubMed  PubMed Central  Google Scholar 

  17. X. Wan, W. Wang, J. Liu et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol 14, 135 (2014)

    Article  PubMed  PubMed Central  Google Scholar 

  18. Higgins J.P.T., Thomas J., Chandler J., et al. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.

  19. S. Linjawi, B.W. Bode, L.B. Chaykin et al. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes Ther. 8(1), 101–114 (2017)

    Article  CAS  PubMed  Google Scholar 

  20. H.W. Rodbard, B.W. Bode, S.B. Harris et al. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. Diabet Med. 34(2), 189–196 (2017)

    Article  CAS  PubMed  Google Scholar 

  21. I. Lingvay, F. Pérez Manghi, P. García-Hernández et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: The DUAL V randomized clinical trial. JAMA 315(9), 898–907 (2016)

    Article  CAS  PubMed  Google Scholar 

  22. L.K. Billings, A. Doshi, D. Gouet et al. Efficacy and safety of ideglira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: The DUAL VII randomized clinical trial. Diabetes Care 41(5), 1009–1016 (2018)

    Article  CAS  PubMed  Google Scholar 

  23. V.R. Aroda, G. González-Galvez, R. Grøn et al. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol 7(8), 596–605 (2019)

    Article  CAS  PubMed  Google Scholar 

  24. A. Philis-Tsimikas, L.K. Billings, R. Busch et al. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes. Diabetes Obes. Metab. 21(6), 1399–1408 (2019)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. R.J. Galindo, B. Moazzami, M.F. Scioscia et al. A randomized controlled trial comparing the efficacy and safety of ideglira versus basal-bolus in patients with poorly controlled type 2 diabetes and very high HbA1c ≥9-15%: DUAL HIGH trial. Diabetes Care 46(9), 1640–1645 (2023)

    Article  PubMed  Google Scholar 

  26. T. Kunt, F.J. Snoek, Barriers to insulin initiation and intensification and how to overcome them. Int. J. Clin. Pract. Suppl. 164, 6–10 (2009)

    Article  Google Scholar 

  27. A.J. Cannon, A. Bargiota, L. Billings et al. Evaluation of the short-term cost-effectiveness of ideglira versus basal insulin and basal-bolus therapy in patients with type 2 diabetes based on attainment of clinically relevant treatment targets. J. Manag. Care Spec. Pharm. 26(2), 143–153 (2020)

    PubMed  Google Scholar 

  28. B. Hunt, M. Mocarski, W.J. Valentine et al. IDegLira versus insulin Glargine U100: A long-term cost-effectiveness analysis in the US setting. Diabetes Ther. 8(3), 531–544 (2017)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. I. Matsuba, A. Kanamori, M. Takihata et al. Canagliflozin increases calorie intake in type 2 diabetes without changing the energy ratio of the three macronutrients: CANA-K study. Diabetes Technol. Ther. 22(3), 228–234 (2020)

    Article  CAS  PubMed  Google Scholar 

  30. S. Rizza, G. Piciucchi, M. Mavilio et al. Effect of deprescribing in elderly patients with type 2 diabetes: iDegLira might improve quality of life. Biomed. Pharmacother. 144, 112341 (2021)

    Article  CAS  PubMed  Google Scholar 

  31. I. Lingvay, Y. Handelsman, S. Linjawi et al. Efficacy and safety of iDegLira in older patients with type 2 diabetes. Endocr. Pract. 25(2), 144–155 (2019)

    Article  PubMed  Google Scholar 

  32. F. Giorgino, I. Caruso, R. Napoli, Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 170, 108478 (2020)

    Article  CAS  PubMed  Google Scholar 

  33. A.B. King, A. Philis-Tsimikas, E.S. Kilpatrick et al. A fixed ratio combination of insulin degludec and liraglutide (IDegLira) reduces glycemic fluctuation and brings more patients with type 2 diabetes within blood glucose target ranges. Diabetes Technol. Ther. 19(4), 255–264 (2017)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author contributions

Y.L. and X.W. conceived the study and prepared the first draft of the report. Y.L. and X.L. conducted the literature search, literature selection and data extraction. Y.Z., X.W., and X.W. made contributions to statistical analyses and data interpretation and reviewed the manuscript. All authors contributed to the article and approved the submitted version.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang, China

    Yang Liu, Xuejing Li, Yingying Zheng, Xiaoli Wang & Xianying Wang

Authors
  1. Yang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xuejing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yingying Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaoli Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xianying Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xianying Wang.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Y., Li, X., Zheng, Y. et al. IDegLira for type 2 diabetes: a systematic review and meta-analysis. Endocrine 83, 648–658 (2024). https://doi.org/10.1007/s12020-023-03543-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-023-03543-z

Keywords

Search

Navigation